SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

As is the case for institutions treating the disease, a majority of the sickle cell patients at SSM Health Cardinal Glennon Children’s Hospital are African American. The hospital recognized the need ...

In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against Larry Robbins’ other long-term stock picks. Larry Robbins is an American hedge fund ...

Picking Monarez would close an unprecedented leadership gap atop the CDC, which is tasked with tracking and responding to a myriad of emerging diseases and health emergencies. Other health ...

LATER THAN 6 A.M. AND LOOKING AHEAD TO NEXT WEEKEND, A HUGE NEW YEAR CELEBRATION AT MYRIAD BOTANICAL GARDENS. IT’S ALL GOING DOWN NEXT SATURDAY FROM 11 A.M. TO 2 P.M. YOU CAN EXPECT MUSIC, CRAFTS, AND ...

High blood pressure affects multiple organs. Not only can hypertension add stress to the heart and damage arteries, leading to heart disease, but it also can cause strokes and kidney disease as ...

The study is the first publication to emerge from the company's ongoing prospective study, Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR). The study found that AROA's Myriad Matrix™ and ...